In Reply: SELECT found that selenium as L-selenomethionine at 200 μg per day did not decrease the risk of prostate cancer in a large randomized group of men whose baseline selenium distribution represents that of the US population. Secondary analyses of selenium supplementation effects by baseline selenium status in the much smaller NPC study (1312 participants vs 35 533 in SELECT) may help understand this outcome: a population of men who are replete in selenium will not benefit from selenium supplementation and may have an increased risk of diabetes.1
Lippman SM, Klein EA, Goodman PJ. Selenium and Vitamin E Supplementation for Cancer Prevention—Reply. JAMA. 2009;301(18):1876–1877. doi:10.1001/jama.2009.627
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: